Xiaoping Li, Wenbin Luo, Yang Tang, Jiangjiao Wu, Junkai Zhang, Shengnan Chen, Lu Zhou, Yu Tao, Yuanjuan Tang, Fengxian Wang, Yu Huang, Pedro A Jose, Li Guo, Chunyu Zeng
AIMS: Doxorubicin is a powerful chemotherapeutic agent for cancer, whose use is limited due to its potential cardiotoxicity. Semaglutide (SEMA), a novel analog of glucagon-like peptide-1 (GLP-1), has received widespread attention for the treatment of diabetes. However, increasing evidence has highlighted its potential therapeutic benefits on cardiac function. Therefore, the objective of this study was to examine the efficacy of semaglutide in ameliorating doxorubicin-induced cardiotoxicity...
March 19, 2024: Redox Biology